CMPX Compass Therapeutics, Inc.

NASDAQ
$0.66

Compass Therapeutics, Inc. (CMPX) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -17.0% since its last earnings release on November 9, 2026.

Compass Therapeutics Missed Consensus Estimates
Monday, November 9, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 7:30 AM ET
Earnings Whisper
-
vs ($0.15)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Compass Therapeutics, Inc.

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.